← 홈

전체 프로그램

ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 227개
ADCBiologicstalePfizerderuxtecan showed encouragi…Phase 1

Dacomitinib (Dacomitinib)

Non-Small Cell Lung Cancer · FRα

#FR#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 75.3%임상시험 46상태 DISCONTINUED
CGTBiologicstaleHistograft Co., Ltd.operatedPreclinical

"Histograft", a bone substitute based on octacalcium phosphate (OCP, "Histograft", a bone substitute based on octacalcium phosphate, "Histograft", a bone substitute based on octacalcium phosphate (OCP) and plasmid DNA encoding VEGFA gene)

Non Union Fracture; Non-Union of Ankle Joint Without Infection · FRα

#FR#CGT#Preclinical#세포유전치료#CAR-T+5
임상시험 45상태 ACTIVE
ADCBiologicstaleCanadian Cancer Trials Groupvedotin, a monoclonal antib…Phase 2

Adavosertib (Adavosertib)

Prostate Cancer · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 66.7%임상시험 45상태 RECRUITING
CGTBiologicstaleSecuraBio-deliveringPhase 3

Duvelisib (Duvelisib)

Indolent Non-Hodgkin's Lymphoma; Follicular Lymphoma · FRα

#FR#CGT#Phase3#세포유전치료#CAR-T+5
효능 ORR 82%임상시험 45상태 RECRUITING
CGTBiologicstaleNovartisPhase 3

tisagenlecleucel (Kymriah, tisa-cel)

Acute Lymphoblastic Leukemia · FRα

#FR#CGT#Phase3#세포유전치료#CAR-T+4
효능 ORR 83.3%임상시험 45상태 DISCONTINUED
CGTBiologicstaleOHSU Knight Cancer InstitutePhase 2

Hyper-CVAD (Hyper-CVAD)

Relapsed/Refractory; B-cell Acute Lymphocytic Leukemia · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+5
효능 ORR 89%임상시험 40상태 RECRUITING
AntibodystaleJanssenPhase 3

Talquetamab (Talquetamab)

Myeloma Multiple; Plasma Cell Leukemia · FRα

#FR#Antibody#Phase3#항체#면역항체+5
임상시험 40상태 DISCONTINUED
CGTBiologicstaleiCell Gene TherapeuticsPhase 1

CD4 CAR T cells (CD4 CAR T cells)

T Cell Lymphoma in Relapse; Refractory T-Cell Lymphoma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+5
효능 ORR 80.3%임상시험 39상태 ACTIVE
CGTBiologicstaleSung-Soo ParkPreclinical

IMiD treatment (IMiD treatment)

Multiple Myeloma, Relapsed; Multiple Myeloma (MM) · FRα

#FR#CGT#Preclinical#세포유전치료#CAR-T+5
효능 ORR 48.3%임상시험 39상태 RECRUITING
ADCBiologicstaleSanofiPhase 2

Belumosudil (Belumosudil)

Plasma Cell Myeloma Refractory · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 74%임상시험 38상태 RECRUITING
CGTBiologicstaleNovartis PharmaceuticalsPhase 2

CTL019 T-cells (CTL019 T-cells)

B-cell Acute Lymphoblastic Leukemia; Relapsed B-cell Acute Lymphoblastic Leukemia · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+5
효능 ORR 82.3%임상시험 37상태 ACTIVE
CGTBiologicstaleHe HuangPhase 1

CAR-T cells chimeric antigen receptor T cells (CAR-T cells chimeric antigen receptor T cells)

Relapsed/Refractory Acute Myeloid Leukemia(AML) · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+5
효능 0%임상시험 32상태 RECRUITING
AntibodystaleRocheVedotin in Relapsed/Refract…Phase 2

Glofitamab/Obinutuzumab (Glofitamab/Obinutuzumab)

Richter Syndrome · FRα

#FR#Antibody#Phase2#항체#면역항체+5
효능 ORR 35.3%임상시험 31상태 RECRUITING
ADCBiologicstaleVerastem, Inc.Phase 2

Defactinib (Defactinib)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 3.2%임상시험 30상태 RECRUITING
ADCBiologicstaleJanssen Research & Development,…Phase 2

Erdafitinib (Erdafitinib)

Muscle Invasive Bladder Urothelial Carcinoma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 46.9%임상시험 30상태 RECRUITING
ADCBiologicstaleCalithera Biosciences, IncPhase 2

Sapanisertib (Sapanisertib)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 18.4%임상시험 30상태 RECRUITING
AntibodystaleMarcela V. Maus, M.D.,Ph.D.Phase 2

Emapalumab (Emapalumab)

Large B-cell Lymphoma; Relapsed Non-Hodgkin Lymphoma · FRα

#FR#Antibody#Phase2#항체#면역항체+4
효능 ORR 60%임상시험 29상태 RECRUITING
ADCBiologicstaleNational Cancer Institute (NCI)vedotin, and venetoclax dem…Phase 2

Larotrectinib (Larotrectinib)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+5
효능 ORR 94.4%임상시험 25상태 RECRUITING
ADCBiologicstaleSeagenPhase 2

brentuximab vedotin (Adcetris, Brentuximab Vedotin - induction)

Refractory Peripheral T-Cell Lymphoma; Relapsed Peripheral T-Cell Lymphoma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 2%임상시험 24상태 ACTIVE
ADCBiologicstaleGlaxoSmithKlinePhase 2

Dabrafenib Mesylate (Dabrafenib Mesylate)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 61%임상시험 24상태 RECRUITING

3 / 12 페이지

← 이전다음 →